At its Breakthrough 2026 event in Madrid, ArisGlobal made a clear statement: AI in life sciences needs to move beyond isolated pilots and into governed, enterprise-wide execution.
The AI-first technology vendor, known for its LifeSphere® platform, announced five major product launches designed to operationalize AI across the pharmaceutical R&D lifecycle. The lineup includes XDI, a next-generation “data intelligence cortex,” three new AI agents within its NavaX suite, and an integrated translation capability aimed at transforming global pharmacovigilance workflows.
Taken together, the announcements reflect a broader industry shift: life sciences companies are no longer asking whether to use AI—but how to scale it across safety, regulatory, clinical, quality, and manufacturing functions without breaking compliance.
XDI: A Cross-Functional AI Cortex
The headline launch is XDI, described by ArisGlobal as a system-agnostic data intelligence cortex.
While many AI tools focus on accelerating individual workflows—automating document review in regulatory or speeding signal detection in safety—XDI aims higher. It is designed to access data across multiple enterprise systems and functions, unifying meaning, context, and governance across traditionally siloed domains.
In practical terms, that means decisions made in pharmacovigilance, regulatory affairs, clinical development, or manufacturing are grounded in shared definitions and aligned evidence.
That’s no small challenge in pharma, where interpretive drift between teams—say, how a safety signal is defined versus how it’s documented in a submission—can create compliance risk.
ArisGlobal positions XDI as an answer to that fragmentation. By providing explainable AI with evidential alignment across functions, the company says it can promote confident AI adoption while reducing risk tied to inconsistent interpretations.
This approach mirrors a broader enterprise AI trend: building centralized intelligence layers rather than deploying disconnected copilots in each department.
Expanding the NavaX Agents Suite
Alongside XDI, ArisGlobal expanded its NavaX Agents Suite with three new AI agents targeting regulatory intelligence, change management, and safety signal analysis.
Intelligence Agents: Automating Regulatory Interpretation
Regulatory submissions are notoriously complex, requiring precise alignment with evolving global guidelines. The new Intelligence Agents automatically interpret regulatory requirements, convert them into rule-based checklists, and assess dossiers generated in LifeSphere Submissions.
Instead of manually cross-checking documents against guidance, teams receive compliance evaluations with justifications and confidence scores.
In a world where agencies like the FDA and EMA continue to update technical standards and submission formats, automation here could significantly reduce review cycles—and audit anxiety.
Distribution Agents: Continuous Compliance Monitoring
Regulatory change doesn’t stop after submission. Distribution Agents are designed to continuously ingest updated regulatory guidance and validate it against internal distribution logic.
If discrepancies arise, the system triggers governed change workflows.
For global pharma companies juggling country-specific variations, that kind of automated monitoring could reduce the risk of outdated or non-compliant distribution practices slipping through the cracks.
Signals Agents: An Orchestrated Safety Assistant
Perhaps the most ambitious of the trio, Signals Agents acts as an intelligent assistant for safety analytics.
Rather than performing a single predefined task, it interprets user intent, selects the appropriate analytical approach, and dynamically orchestrates workflows across safety data, analytics engines, and expert judgment layers.
ArisGlobal describes it as an “active intelligence partner,” hinting at agentic AI capabilities that go beyond static dashboards. In pharmacovigilance—where signal detection and assessment are mission-critical—such orchestration could accelerate insight generation without sacrificing rigor.
NavaX Translation: Cutting Case Intake From Hours to Seconds
Operational friction in life sciences often hides in mundane but mission-critical tasks. Case intake in global pharmacovigilance is one such area.
ArisGlobal announced a strategic partnership with TransPerfect Life Sciences to embed certified translation capabilities directly into LifeSphere workflows.
Using intelligent language detection, non-English safety forms are automatically routed for translation via pharma-specific language models and expert linguists. Through API integration, translated forms are returned directly into LifeSphere.
The company claims translation management time drops from roughly five hours per case to under a minute.
If that holds in practice, it’s a meaningful efficiency gain for organizations handling high volumes of adverse event reports across multiple regions.
More importantly, it reduces manual intervention—often a bottleneck in compliance-sensitive processes.
The Bigger Industry Context
AI adoption in life sciences has surged over the past three years, but operationalization remains uneven.
Many pharma companies have deployed AI for targeted use cases—document classification, signal prioritization, or clinical trial optimization. However, scaling those pilots across functions while maintaining validation, traceability, and governance has proven difficult.
ArisGlobal’s announcements align with a growing push toward enterprise AI architectures that emphasize explainability and auditability. Regulatory scrutiny is intensifying globally, and black-box models are a hard sell in regulated environments.
By focusing on explainable AI, evidential alignment, and governed workflows, ArisGlobal is targeting a core concern of CIOs and R&D leaders: how to innovate without introducing compliance risk.
Aman Wasan, CEO of ArisGlobal, framed the challenge succinctly: “The challenge for life sciences isn’t just adopting AI—it’s operationalizing it at scale with consistency, governance, and real business impact.”
Ann-Marie Orange, CIO and Global Head of R&D, added that the shift is from automating individual tasks to orchestrating intelligence across operational ecosystems.
That framing captures the moment. In pharma, AI success increasingly depends not on isolated productivity gains but on system-wide coherence.
From Experimentation to Enterprise Backbone
Breakthrough 2026’s theme—“Operationalizing AI”—underscores the company’s strategic direction.
With XDI as a unifying data intelligence layer, expanded AI agents for regulatory and safety functions, and embedded translation for global case intake, ArisGlobal is positioning LifeSphere as an enterprise AI backbone for life sciences.
Whether customers can seamlessly integrate these capabilities into complex legacy environments will determine how transformative the rollout becomes.
But one thing is clear: in regulated industries like pharma, the next wave of AI isn’t about flashier models. It’s about trust, governance, and cross-functional alignment at scale.
Power Tomorrow’s Intelligence — Build It with TechEdgeAI
